From stigma to scale: How bladder control therapies are evolving from hidden struggle to healthcare priority

Why has urinary incontinence remained stigmatized despite affecting hundreds of millions globally?

Urinary incontinence (UI) continues to be one of healthcare’s most common but under-spoken conditions, even though epidemiological studies now estimate that about 423 million adults aged 20 or older worldwide experience some form of UI. Prevalence in women ranges between 25% to 45%, while in men it is lower but still substantial, particularly in older age groups. The frequent underreporting of symptoms is rooted in social stigma, misconceptions that leakage is “just part of aging,” and patient discomfort in discussing intimate issues with clinicians. Many people endure symptoms for six to nine years before seeking medical care, according to clinical reports. Physicians themselves often do not initiate discussions: in primary care surveys, significant numbers report rarely or never asking patients about urinary incontinence.

Compounding this is the mental health impact. Researchers have found strong associations between urinary incontinence and elevated levels of depression, stress, and lowered self-esteem, particularly in women with stress or urge incontinence. In many societies, the taboo around incontinence prevents conversations, delays diagnoses, and undermines quality of life, despite the large numbers affected.

How are new therapies from Medtronic, Boston Scientific, and Axonics changing the perception of bladder control disorders?

Therapies being developed and approved now are helping to upend old assumptions about incontinence being untreatable or only manageable with pads and lifestyle changes. Medtronic’s Altaviva device, for example, represents a shift toward implantable tibial neuromodulation that is minimally invasive, patient-friendly in maintenance (with long battery life, reduced need for frequent adjustments, MRI compatibility), and more immediately usable after implantation. Axonics’ sacral neuromodulation systems have shown durable symptom improvements in urge urinary incontinence and mixed incontinence in clinical studies. Boston Scientific’s acquisition of Axonics has signaled increasing consolidation and strategic prioritization of bladder control therapies as core growth areas.

These advances are helping change perceptions not only among patients but also among clinicians. The availability of newer, less burdensome device options reduces “treatment inertia.” Physicians are more willing to recommend device-based therapies when risks are lower, procedures are simpler, and long-term outcomes are clearer. Insurers and regulatory bodies are beginning to recognize urge incontinence and mixed incontinence as conditions with serious quality-of-life and economic costs, which strengthens the case for supporting newer interventions.

What role does patient awareness, stigma reduction, and education play in driving adoption of bladder health devices?

Awareness is one of the most powerful levers for scale. Surveys show that many people affected by urinary incontinence feel ashamed or embarrassed: in the U.S., 44% of Americans with urinary incontinence report they do not want to tell their doctor about the issue due to embarrassment. In older men (aged 60+), roughly 58% of those experiencing UI have never discussed it with a clinician. Many normalize or dismiss leakage as part of aging or believe nothing can be done.

Patient narratives, advocacy groups, and media coverage are helping to break silence. Public health campaigns, women’s health organizations, and pelvic floor education in postpartum care are raising awareness of incontinent symptoms and treatment options. Education for healthcare providers is also essential: studies indicate that many primary care and internal medicine physicians still fail to routinely ask about UI, and sometimes default to recommending pads instead of exploring therapeutic or device-based interventions. Better training, more patient-clinician openness, and clearer information can shorten the delay between symptom onset and treatment.

How are healthcare systems, insurers, and hospitals addressing the economic burden of untreated bladder control issues?

The cost of untreated or under-treated UI is high, both for individuals and health systems. Frequent urinary leakage leads to skin infections, sleep disturbances, social isolation, mental health burden, lost productivity, and increased use of absorbent products. Health systems are beginning to see that early intervention and device-based therapies may reduce long-term costs by preventing complications.

Market reports show that the global urinary incontinence devices market (which includes catheters, slings, electrical stimulation devices, artificial urinary sphincters, etc.) was valued at around USD 3.6 to 4.2 billion in 2023-2024 depending on definition, and is forecast to grow to between USD 7.3 and 8.0+ billion by 2030-2033, with compound annual growth rates in the range of 6.5% to over 10%. Choosing to invest in evidence-based device therapies can be cost-justified if reimbursement, regulatory support, and clinician adoption align.

Hospitals and outpatient surgical centers are increasingly evaluating value-based procurement: devices that offer high durability, lower maintenance costs, and fewer complications tend to be preferred. Insurance reimbursement is changing too in many markets, with new billing codes or expanded coverage for neuromodulation, electrical stimulation devices, and sling procedures. Regions with aging populations, high prevalence of obesity and diabetes (which amplify incontinence risk), and higher healthcare spending power are leading adoption.

Why is the global bladder control devices market expected to grow rapidly over the next decade?

Multiple converging global trends support strong market growth. Aging populations are expanding in North America, Europe, and increasingly Asia-Pacific, where older women in particular are most at risk for stress and urge incontinence. Rates of obesity, diabetes, and prostate disease are increasing, broadening the pool of potential patients. Technological innovation—miniaturization, rechargeable or long-life battery systems, MRI compatibility, better materials—are improving patient experience. The rise of outpatient minimally invasive procedures further reduces costs and barriers for adoption.

Recent market data shows the global urinary incontinence treatment devices market was approximately USD 3.60-4.10 billion in 2024 depending on source. Forecasts suggest this could reach USD 5.36 billion by 2030 under an ~8.3 % CAGR (per one estimate), or USD ~7.28-8.00 billion by 2030-2033 depending on the inclusion of certain device categories. Growth in the urge incontinence segment is expected to outpace stress in many parts of the world because of newer device therapies and neuromodulation gains. Asia-Pacific shows the fastest growth rate in many reports, even as North America remains the largest market by revenue.

What lessons can patients, investors, and clinicians derive from the shift from stigma to scale in bladder health?

Patients should know that effective therapies are increasingly accessible and less burdened by invasiveness or lifestyle disruption. They no longer need to treat incontinence as a private struggle alone. Asking doctors about device options, neuromodulation, surgical slings, and newer non-implantables can lead to earlier relief and better quality of life.

Clinicians must be proactive: screening for urinary incontinence in routine visits, discussing all therapy options, and staying updated on emerging device approvals and neuromodulation innovations. Hospitals and health systems that invest in patient-centric devices (long battery life, fewer follow-ups, simpler procedures) often see better uptake, lower costs, and higher patient satisfaction.

Investors ought to recognize bladder control therapies as a high-potential, but under-leveraged segment in medtech. Devices markets for urinary incontinence show multi-billion dollar growth trajectories, and companies differentiating on patient experience, lower invasiveness, and regulatory trailblazing are likely to outperform. Strategic acquisitions (like Boston Scientific’s purchase of Axonics), innovation in neuromodulation, and expansion into emerging markets are signals of where the market is heading.

What does the future hold as bladder control moves from taboo to mainstream healthcare concern?

The path ahead involves several defining trends. First, expanded regulatory approvals not just for novel devices, but for indications beyond stress and urge incontinence—mixed incontinence, overflow, and pediatric/postpartum contexts. Second, reimbursement reform: payors will need to catch up to support therapies that reduce long-term costs rather than focusing only on short-term expense. Third, device companies will compete on usability: less visible implants, better battery longevity, minimal maintenance, smart/connected features, integration with telehealth.

Another trend is the shift from purely device-centred care toward integrated bladder health ecosystems: combining diagnostics, wearable monitoring, behavioral therapy, surgical/implantable devices, and patient follow-up. Public awareness campaigns, advocacy, and destigmatization will accelerate demand, leading to larger addressable markets.

Geographically, we can expect Asia-Pacific, Latin America, and some emerging markets to account for increasing share of demand, provided device cost, reimbursement, and distribution challenges are addressed. Meanwhile, leading companies that already have scale in North America and Europe will seek growth via partnerships, licensing, and incremental device innovation.

Bladder control therapies are finally moving beyond the shadows. From culture and stigma that long silenced millions, to innovations that reduce invasiveness and normalize treatment, the shift from hidden struggle to healthcare priority is underway. As patients find voice, as clinicians expand treatment options, and as investors realign toward value-based innovation, urinary incontinence may soon become one of the best examples of a medtech transformation built on both social need and technological breakthrough.